{"ModuleTitle": "Company Description", "CompanyName": "Heska Corporation", "Symbol": "HSKA", "Address": "3760 ROCKY MOUNTAIN AVENUE, LOVELAND, Colorado, 80538, United States of America", "Phone": "9704937272", "Industry": "Biotechnology: In Vitro & In Vivo Diagnostic Substances", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Unless we state otherwise or the context otherwise requires, the terms \"Heska,\"\r\n\"we,\" \"our,\" \"us\" and the \"Company\" refer to Heska Corporation and its\r\nconsolidated subsidiaries.\r\nOur Certificate of Incorporation, as amended (the \"Charter\"), authorizes three\r\nclasses of stock: Original Common Stock, Public Common Stock, and Preferred\r\nStock.  Pursuant to an NOL Protective Amendment to the Charter adopted in 2010,\r\nall shares of Original Common Stock then outstanding were automatically\r\n\r\n                                      -1-\r\n--------------------------------------------------------------------------------\r\n\r\n\r\n\r\nreclassified into shares of Public Common Stock.  Our Public Common Stock trades\r\non the Nasdaq Stock Market LLC.  In this Annual Report on Form 10-K, references\r\nto \"Public Common Stock\" and \"common stock\" are references to our Public Common\r\nStock, unless the context otherwise requires.\r\nOverview\r\nWe sell veterinary and animal health diagnostic and specialty products.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f28%2f0001038133-20-000013.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Catherine I. Grassman", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Glenn R. Frank", "title": "Vice President-Research & Development"}, {"name": "Kevin S. Wilson", "title": "President, Chief Executive Officer & Director"}, {"name": "Nancy Wisnewski", "title": "Chief Operating Officer & Executive Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}